The Africa In Vitro Diagnostics (IVD) Market to Reach $1.49 Billion by 2030 at a CAGR of 2.8% during the Forecast Period, Says Meticulous Research®. According to this latest publication from Meticulous Research®, the Africa in vitro diagnostics market is expected to register a CAGR of 2.8% from 2023 to 2030 to reach $1.49 billion by 2030. The high prevalence of infectious diseases, the rising burden of chronic diseases, the increasing initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major factors driving the growth of the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are some of the major challenges to the market’s growth.
Here are the top 10 companies operating in the Africa IVD Market
Abbott Laboratories (U.S.)
Founded in 1888 and headquartered in Illinois, U.S., Abbott Laboratories is engaged in the discovery, development, manufacturing, and sale of healthcare products. The company offers a wide range of products to the diagnostics, medical devices, nutrition, and branded generic pharmaceuticals markets. Abbott operates worldwide through four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company operates in the in vitro diagnostics market through its Diagnostics business segment, which is further divided into Core Laboratory, Rapid Diagnostics, Point of Care, and Molecular business categories. Among these, the Rapid Diagnostics business became a part of Alere Inc. (U.S.), a diagnostic device manufacturer and service provider, through the acquisition by Abbott in October 2017.
The company has a wide geographic presence and a strong distribution network through direct and indirect channels in various countries, including Africa. The company has 90 manufacturing facilities globally, of which 24 manufacturing sites are engaged in developing diagnostic products. Some of its subsidiaries operating in Africa include Abbott Kenya Limited (Kenya), Abbott Laboratories South Africa (Pty) Ltd. (South Africa), and Alere Healthcare Nigeria Limited (Nigeria).
Becton, Dickinson and Company (U.S.)
Founded in 1887 and headquartered in New Jersey, U.S., Becton, Dickinson and Company (BD) is a medical technology company that manufactures and sells a wide range of medical devices, laboratory equipment, and diagnostic products used by healthcare institutions, clinical laboratories, pharmaceutical companies, and research centers. The company operates through three business segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Life Sciences business segment offers products through two major categories: Integrated Diagnostic Solutions (Diagnostic Systems and Preanalytical Systems) and Biosciences. The Diagnostic Systems category offers numerous products with clinical and industrial applications. These products include molecular testing systems for infectious diseases & women’s health, liquid-based cytology systems for cervical cancer screening, culturing systems, rapid diagnostic assays for testing respiratory infections, microorganism identification, and drug susceptibility systems.
BD has a direct presence in the U.S., Brazil, Canada, China, France, Spain, the U.K., Germany, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Singapore, and the Netherlands through its manufacturing and sales operations. The R&D facilities of the company are located in China, France, India, Ireland, the U.S., and Singapore. BD has a wide global distribution network and markets its products through independent distribution channels directly to hospitals, healthcare institutions, and independent sales representatives.
bioMérieux SA (France)
Founded in 1963 and headquartered in Marcy-l’Étoile, France, bioMérieux SA is engaged in developing a wide range of products & solutions, including reagents, instruments, and software for clinical diagnostics. The company offers products for microbiology, immunoassay, molecular biology, and industrial applications. bioMérieux operates through two reportable segments: Clinical Applications and Industrial Applications. In the Clinical Applications segment, the company’s products are used for infectious disease diagnostics, while in Industrial Applications, products are used to detect microorganisms in agri-food, pharmaceuticals, and cosmetics. The company’s major products under molecular biology solutions include BIOFIRE FILMARRAY molecular biology solutions, VIDAS B∙R∙A∙H∙M∙S PCT test, VITEK range, and ARGENE range.
The company has a direct presence and a strong distribution network across 160 countries through 44 subsidiaries and 15 production sites. The activities carried out at these sites include the production, sales, and distribution of reagents for ready-to-use media for microbiology and industrial applications, research & development, and commercial and administrative functions. The major subsidiaries of company operating in Africa are bioMérieux South Africa Pty Ltd. (South Africa), bioMérieux Algérie E.u.r.l. (Algeria), bioMérieux Kenya Ltd. (Kenya), and bioMérieux West Africa SAU (Côte d’ivoire).
Danaher Corporation (U.S.)
Founded in 1969 and headquartered in Washington, D.C., U.S., Danaher Corporation is involved in the designing, manufacturing, and marketing of medical, professional, industrial, and commercial products & services for various end users. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Danaher operates in the in vitro diagnostics market through its Diagnostics business segment and offers a wide range of products, including analytical instruments, reagents, consumables, software, and services. These products are used in various healthcare settings such as hospitals, physicians’ offices, reference laboratories, and other critical care settings to diagnose diseases. This segment is further categorized into Clinical Lab Diagnostics, Critical Care Diagnostics, and Anatomical & Pathological Diagnostics.
Danaher Corporation has a total of 212 R&D, manufacturing, sales, distribution, service, and administrative facilities in more than 60 countries worldwide. The company’s manufacturing facilities are located in North America, Europe, Asia, and Australia. As of 2019, 60,000 people were employed by the company, out of which 21,000 were in U.S.-based facilities and 39,000 were employed outside of the U.S.
Danaher Corporation has several subsidiaries across the globe, of which Beckman Coulter, Inc. (U.S.), Cepheid (U.S.), Leica Biosystems Nussloch GmbH (Germany), HemoCue AB (Sweden), and Radiometer Medical ApS (Denmark) offer instruments & reagents for in vitro diagnostic applications.
F. Hoffmann-La Roche Ltd. (Switzerland)
Founded in 1986 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd. is a research-based healthcare company majorly engaged in creating innovative medicines and providing solutions for diagnostics. The company operates through two major business segments: Pharmaceuticals and Diagnostics, and offers centralized and point-of-care kits & reagents, advanced staining reagents, molecular diagnostic tests, and blood screening tests through its diagnostics division.
The Diagnostics segment is further categorized into Core Lab, Molecular Lab, Point of Care, Diabetes Care, and Pathology Lab. The Diagnostics division manufactures equipment & reagents for research & medical diagnostic applications. F. Hoffman-La Roche has 20 manufacturing sites and 27 research & development sites engaged in Pharmaceuticals and Diagnostics operations worldwide. The company has subsidiaries in African countries such as Nigeria, Kenya, Ghana, Cote d’Ivoire, and Algeria.
Meticulous Research in its latest publication on Africa IVD Market has predicted the growth of 2.8% during the forecast year 2023-2030.
QIAGEN N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. develops & sells instruments, consumables, and digital bioinformatics solutions for oncology, infectious diseases, sexual & reproductive health, TB management, precision diagnostics, and point-of-care testing research. The company operates in two business segments: Molecular Diagnostics and Life Sciences. Through the Molecular Diagnostics segment, Qiagen N.V. offers a wide range of molecular diagnostic technologies, including automated systems, assays, markers, and reagents used to diagnose cancer and infectious diseases.
QIAGEN N.V. offers its products to more than 500,000 customers and has 35 subsidiaries operating in 35 countries, including the U.S., Canada, Germany, Spain, the U.K., France, Italy, the Netherlands, Sweden, Turkey, Sweden, Brazil, Mexico, China, Hong Kong, Taiwan, South Korea, India, and South Africa. Qiagen N.V. has manufacturing and production facilities in Germany, the U.S., the U.K., and China.
The company has a strong distribution network through its partners across 60 countries worldwide and operates in the Africa IVD market through its subsidiary QIAGEN SA (Pty) — Ltd South Africa.
Siemens Healthineers AG (Germany)
Founded in 1847 and headquartered in Erlangen, Germany, Siemens Healthineers AG is engaged in developing and selling a wide range of products with medical imaging applications, laboratory diagnostics, and point-of-care testing. The company also offers digital health platforms for various clinical specialties and laboratories across the globe. The company operates through four business segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The company operates in the in vitro diagnostics market through its Diagnostics segment, offering in vitro diagnostic products & services to healthcare professionals working in molecular diagnostics, point-of-care diagnostics, and laboratories.
Siemens has a direct presence in more than 70 countries, including the U.S., Canada, Germany, the U.K., France, Italy, Spain, Denmark, Sweden, Switzerland, Belgium, India, China, Japan, Australia, New Zealand, and the Republic of Korea. The company also has a strong geographic presence through its subsidiaries and production sites across the U.S., Germany, China, Europe, the Commonwealth of Independent States (C.I.S.), Africa, the Middle East, the Americas, Asia, and Australia. Furthermore, the company has distribution channels across the Middle East, the Americas, Asia, and Australia.
Some of the major subsidiaries of the company are Siemens Healthcare (South Africa), Varian Medical Systems Africa (Pty) Ltd. (South Africa), Siemens Healthcare Proprietary Limited (South Africa), Varian Medical Systems Algeria Spa., (Algeria), and VMS Kenya, Ltd, (Kenya).
Thermo Fisher Scientific Inc. (U.S.)
Founded in 2006 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific Inc. is a biotechnology company engaged in life sciences research, improving patient diagnostics, and increasing laboratory productivity. The company operates through four business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company operates in the IVD market through its Specialty Diagnostics segment and offers diagnostic test kits, reagents, culture media, instruments, and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.
Some of the major brands of Thermo Fisher are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. In June 2019, Thermo Fisher Scientific sold its Anatomical Pathology business to PHC Holdings Corporation (Japan), which primarily offered products for cancer diagnosis & medical research in histology, cytology, and hematology applications.
The company has a direct presence through its regional offices and production sites in the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, the UAE, India, China, Japan, Australia, and the Republic of Korea. Some of the major subsidiaries of the company are Thermo Electron (Proprietary) Limited (South Africa), Thermo Electron Corporation (Proprietary) Limited (South Africa), and Winter Breeze Trading 129 Pty. Ltd (South Africa).
Bio-Rad Laboratories, Inc. (U.S.)
Founded in 1952 and headquartered in California, U.S., Bio-Rad Laboratories, Inc., is a distributor and manufacturer of clinical diagnostics products and life science research. The company supplies and produces a wide range of systems and products for healthcare, analytical chemistry, and life science research. Bio-Rad Laboratories operates through two reportable segments: Clinical Diagnostics and Life Sciences. The company provides 3,000 products in the Clinical Diagnostic segment, covering over 300 clinical diagnostics tests, including IVD. Major clients for clinical diagnostics are physician offices, diagnostic reference laboratories, hospital laboratories, and transfusion laboratories.
The company has a direct distribution channel in more than 35 countries outside the U.S., including Algeria, Ghana, Malawi, Tanzania, Nigeria, South Africa, and Uganda, through its subsidiary, Bio-Rad Laboratories (Pty) Limited (South Africa).
Illumina, Inc. (U.S.)
Founded in 1998 and headquartered in California, U.S., Illumina, Inc., is a producer, marketer and developer of sequencing and array-based solutions for genomic analysis. The company operates through two business segments: Core Illumina and Graill. Illumina operates in the IVD market through its Core Illumina segment by providing NGS platforms for diagnostic use. The company offers its services to molecular diagnostic laboratories, government laboratories, academic institutions, hospitals, genomic research centers, biotechnology companies, consumer genomics companies, pharmaceuticals, and commercial companies.
The Core Illumina segment includes Consumables and Instruments, which are the core operations of Illumina. The company markets and distributes products directly to customers in North America, Latin America, Europe, and Asia-Pacific. Additionally, the company has a network of life-science distributors in certain markets within Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
In April 2020, the company donated sequencing systems and related consumables worth USD 1.4 million to support COVID-19 surveillance across 10 African countries, including the Democratic Republic of the Congo, Ethiopia, Egypt, Ghana, Mali, Kenya, Nigeria, South Africa, Senegal, and Uganda.
Authoritative Research on the Africa IVD Market – Opportunity Analysis and Industry Forecast (2023-2030)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
